XiMIS Medical Secures Tens of Millions in Series A Funding Led by Shenzhen Capital Group to Advance Precision Aesthetic Devices

Another Heavy “Cannon” for Domestic Energy-Based Aesthetic Devices!

VCBeat has exclusively learned that Themis Medical Technology (Shenzhen) Co., Ltd. (“Themis Medical”) completed its tens-of-millions-yuan Series A financing in November 2023, led by Shenzhen Capital Group Co., Ltd. (“SCGC”). The funds raised will be used for new product research and development and capacity expansion, providing strong support for Themis Medical’s strategy to become a comprehensive provider of localized and internationalized diagnostic and therapeutic solutions in the medical aesthetics field.

Themis Medical

Themis Medical, established in October 2022 and headquartered in Bao'an District, Shenzhen, is an innovative medical technology enterprise dedicated to human beauty and health, integrating R&D, manufacturing, sales, and services. Its founding team members hail from leading domestic and international medical device companies, bringing over a decade of extensive experience in the R&D, marketing, and production management of medical aesthetic products.

The company focuses on the medical aesthetics sector and was the first to proposeThe integrated concept of "diagnosis and treatment" in medical aesthetics enables a leap from traditional experience-based therapies to precision medicine.Our core product portfolio encompasses comprehensive solutions for medical aesthetics departments, covering ultrasound, radiofrequency, optical technologies, and skin analysis. Currently, we offer the Intelligent Ultrasound Cannon (Hunan Medical Device Registration No.: 20232090698) and the Gold Ultrasound Cannon (Hunan Medical Device Registration No.: 20232090698). Both devices feature integrated diagnosis and treatment capabilities as well as precise therapeutic functions.

Themis Medical’s Self-Developed Intelligent Ultrasonic Cannon (Top) and Gold Ultrasonic Cannon (Bottom)

Ultrasound-based anti-aging treatments can generate sufficient energy through focused ultrasound points to precisely target the dermis, superficial subcutaneous fat layer, and the SMAS (Superficial Musculoaponeurotic System) fascial layer without damaging the epidermis. This process helps lift facial contours, tighten skin, and combat signs of aging by addressing issues such as laxity, sagging, and wrinkles caused by skin aging. In terms of depth of action, ultrasound-based therapies are among the few non-invasive aesthetic treatments currently available that can reach the depth of the SMAS fascial layer.

In China, there is an urgent need for professional, compliant, safe, and high-end products and solutions in both the ultrasound-based anti-aging treatment sector and the medical aesthetics energy-based device market, to meet the demands of clinical practice and aesthetic seekers.

Guided by the philosophy of "making humanity more beautiful and healthier," Ximis Medical has developed the Intelligent Ultrasonic Cannon and the Golden Ultrasonic Cannon,Pioneered the integration of medical-grade diagnosis and treatment in energy-based aesthetic devices.Utilization during the diagnostic phaseUltrasound Image Navigation, precisely targeting the depth of the fascial layer to achieve intelligent skin localization for “rapid 1-minute diagnosis across 8 major areas.” The treatment phase integratesLarge Focal Spot, Super Pulse, AI-powered adaptive adjustment of energy-based techniquesIntelligent sensing technology, hundred-micron registration technology.Painless, non-invasive, and with no downtime, allowing beauty seekers to walk in and out immediately for a safe transformation.

Ultrasound Imaging Navigation for Intelligent Ultrasound Cannon Devices. Image provided by Ximis Medical.

It is reported that more than 10 R&D projects at Ximis Medical are currently progressing in an orderly manner, and CE certification for overseas markets has also been initiated.

For this round of financing,Ms. Yang Qian, General Manager of Themis Medicalstated: “First and foremost, we extend our sincere gratitude to Shenzhen Capital Group Co., Ltd. (SCGC) and the Hongtu Medical Health Industry Fund for their support and recognition of Themis Medical. Over the past year since its establishment, Themis Medical has experienced rapid growth in both scale and strength. As a domestic aesthetic medical device company with exceptional strength and potential, Themis Medical is committed to achieving precision in aesthetic treatments through relentless innovation, R&D, and promotion of new medical technologies. By doing so, we aim to disrupt traditional aesthetic medicine models, establish a new paradigm of medical-grade precision therapy, facilitate the transition from experience-based to precision-based aesthetic medicine, and usher in a new era of integrated diagnosis and treatment in the aesthetic medicine industry.”

Currently, Ximis Medical has launched a medical-grade intelligent ultrasound device that integrates diagnosis and treatment. Future new products will be developed in accordance with the precise standards of medical-grade devices, continuously introducing more aesthetic medicine products featuring high-end, cutting-edge technologies to the market, and providing the most professional comprehensive solutions for aesthetic diagnosis and treatment worldwide.

This powerful alliance is poised to achieve even greater success in the future medical aesthetics market, contributing more strength to the cause of enhancing human beauty. The grand era of China’s medical aesthetics industry has begun. We are fully confident in navigating the upcoming transformations in the medical aesthetics market, building a safe, efficient, and comfortable medical aesthetics health ecosystem, and creating value while sharing rewards.”

Mr. Xiao Haibo, Director of Themis Medicalstated: “With the development of the global economy, the professional medical aesthetics market is experiencing rapid growth. However, medical aesthetic devices remain at a relatively low level of sophistication and fail to adequately meet customer demands. The founding team of Ximis comes from Mindray and is committed to launching professional medical aesthetic device solutions to better address current market needs. I am confident that Ximis has a promising future.”

Yi Hongxiang, Partner of SCGC Hongtu Healthcare Industry Fundstated: “We are highly optimistic about the growth potential of the global medical aesthetics market. With rising living standards and an aging global population, consumer demand for beauty and anti-aging solutions is intensifying, creating clear opportunities for domestic substitution and overseas expansion. The Themis team brings years of experience in the healthcare industry, with deep technical expertise and sustained R&D capabilities. It possesses comprehensive strengths in developing a full pipeline of high-end energy-based medical aesthetic devices, building an ecosystem, and ensuring product compliance. We look forward to collaborating with the Themis team to advance the application of acoustic, optical, electrical, and magnetic technologies in both medical and consumer sectors, establishing Themis Medical as a leading enterprise in China’s high-end energy-based medical aesthetic device industry.”

Shenzhen Capital Group Co., Ltd. is committed to its mission of discovering and empowering great enterprises, striving to be a discoverer and cultivator of innovative value. Since its establishment in 1999, SCGC has managed total assets exceeding RMB 460 billion, invested in more than 1,700 innovative high-tech companies, among which 261 have achieved public listings. Its portfolio spans industries such as information technology, biotechnology/healthcare, new energy/energy conservation and environmental protection, new materials, intelligent manufacturing, internet, and consumer goods/modern services, covering the entire lifecycle of enterprises.

Established in 2018, the SCGC Hongtu Medical Health Industry Fund is the first medical health industry fund launched by Shenzhen Capital Group Co., Ltd. (SCGC) as part of its “specialization” strategy. The fund focuses on identifying high-quality investment targets with strong innovation capabilities and significant growth potential, thereby driving industrial development. Its portfolio includes outstanding companies such as Akeso, YHLO, Easysight Medical, Hannovate Medical, Medcaptain, Union Medical, 3N Technology, Yuanhua Intelligence, Huasheng Medical, Kangsheng Medical, Leadcom, Helixgene, and Like Technology.